Atypical fibroxanthoma of the skin.

Starink, Th. M.; Hausman, R.; Delden, L. van; Neering, H

doi:10.1111/j.1365-2133.1977.tb15062.x

Cited by 53 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(4-10) Other terms for AFX have been pseudocarcinoma, fibrosarcoma, paradoxical fibrosarcoma, pseudosarcomatous dermatofibroma, pseudosarcomatous xanthofibroma, and pseudosarcomatous reticulohistiocytoma. (11, 12) AFX has also been considered as a superficial, more benign variant of undifferentiated pleomorphic sarcoma, formerly known as pleomorphic malignant fibrous histiocytoma. (12)…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence and Clinical Features of Rare Cutaneous Malignancies in Olmsted County, Minnesota, 2000 to 2010

et al. 2017

View full text Add to dashboard Cite

Background The incidence of rare cutaneous malignancies is unknown. Current estimates of rare cutaneous malignancy incidences are based on broad epidemiologic data or single institution experiences, not population-based data. Objective To determine the incidence of several rare non-melanoma skin cancers. Methods & Materials We conducted a retrospective chart review of a population-based cohort between the years 2000 and 2010. Residents of Olmsted County, Minnesota, who were diagnosed with a biopsy-proven non-melanoma skin cancer - excluding basal cell carcinoma and squamous cell carcinoma - were included in this study. The primary outcome was tumor incidence. Additionally, we extracted patient demographics, tumor characteristics, treatment modalities, and outcomes. Results The age- and sex-adjusted incidences per 100,000 persons of multiple rare cutaneous malignancies were: atypical fibroxanthoma (1.8), sebaceous carcinoma (0.8), dermatofibrosarcoma protuberans (0.4), microcystic adnexal carcinoma (0.7), eccrine carcinoma (0.4), eccrine porocarcinoma (0.2), and leiomyosarcoma (0.2). Conclusion We report population-based incidences and clinical characteristics for these rare cutaneous malignancies. The immune status and smoking status of patients and the treatment and outcomes of these tumors are reported. Additional studies in a broader population are needed to further define the epidemiology and outcomes of these malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

“…(12) Depending on the modality of treatment, the recurrence rates range from 0–16%(11, 12, 14-17) but likely 7–9%. (12) Metastatic rate ranges from 0.5–4%.…”

Section: Discussionmentioning

confidence: 99%

Incidence and Clinical Features of Rare Cutaneous Malignancies in Olmsted County, Minnesota, 2000 to 2010

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Features associated with metastasis include recurrence, vascular invasion, large tumor, deep tissue invasion and tumor necrosis (Giuffrida TJ et al 2004; Helwig EB and May D, 1986). It has been analyzed that these locally invasive and/or metastasizing lesions may have initially been MFH, squamous cell carcinoma or malignant melanoma, rather than AFX (Giuffrida TJ et al 2004; Starink TH et al 1977). …”

Section: Prognosis and Treatmentmentioning

confidence: 99%

Atypical Fibroxanthoma

Sakamoto

2008

Clinical medicine. Oncology

View full text Add to dashboard Cite

Atypical fibroxanthoma (AFX) is a nodular dermal ulcerative lesion with a favorable prognosis. AFX most commonly occurs on sun-exposed skin in elderly individuals. AFX is characterized by its association with ultraviolet radiation, not only from a clinical aspect, but also from a molecular aspect. Making a diagnosis of AFX is challenging, and it is important to differentiate it from squamous cell carcinoma and malignant melanoma. Histological features and combined immunohistochemical markers are necessary for a definitive diagnosis (i.e., an absence of immunostaining for cytokeratins, S100 and HMB45 in AFX is helpful for excluding both squamous cell carcinoma and malignant melanoma). AFX, as well as MFH (malignant fibrous histiocytoma), is a fibrohistiocytic lesion with myofibroblastic differentiation. AFX is considered to be a different lesion from MFH. AFX and MFH might share the same pathway which determines their morphology. However, they may have different pathways in development which determine their biological behavior.

show abstract

“…The tumor is typically exophytic and nodulo‐ulcerative. It often occurs on the head and neck of elderly individuals on a background of skin with actinic or radiation damage 11 . It may, however, occur on the trunk or extremities of younger people.…”

Section: Introductionmentioning

confidence: 99%

Mohs Surgery Report: Spindle Cell Fibrohistiocytic Tumors: Classification and Pathophysiology

Dzubow

1988

The Journal of Dermatologic Surgery and Oncology

View full text Add to dashboard Cite

Four patients with spindle cell cutaneous fibrohistiocytic neoplasms are presented. A classification scheme for this group of tumors is discussed along with the histologic and immunohistochemical criteria needed to establish the diagnosis. Cutaneous malignant fibrous histiocytoma (atypical fibroxanthoma) may behave biologically as a neoplastic rather than reactive mesenchymal tumor with definite invasive and metastatic potential.

show abstract

Atypical fibroxanthoma of the skin.

Cited by 53 publications

References 20 publications

Incidence and Clinical Features of Rare Cutaneous Malignancies in Olmsted County, Minnesota, 2000 to 2010

Incidence and Clinical Features of Rare Cutaneous Malignancies in Olmsted County, Minnesota, 2000 to 2010

Atypical Fibroxanthoma

Mohs Surgery Report: Spindle Cell Fibrohistiocytic Tumors: Classification and Pathophysiology

Contact Info

Product

Resources

About